Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

Raltegravir is the preferred INSTI for for treatment of antiretroviral-naïve pregnant women in the US Perinatal Guidelines, alongside Dolutegravir, and for late pregnancy. There are relatively limited information available on its use during early pregnancy, particularly the peri-conception period. The aim of the study is to assess "real-world" maternal, fetal and newborn outcomes following RAL use during pregnancy through pooled analysis of individual patient data from observational studies participating in the European Pregnancy and Paediatric Infections Cohort Collaboration.

Start Date20 Feb 2023

Sponsor / Collaborator-

NCT03954327

/ CompletedPhase 2IIT

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

Start Date01 Mar 2021

Sponsor / Collaborator

University of Alberta

[+1]

NCT04258475

/ Unknown statusPhase 4IIT

The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

The purpose of this study is to measure change in raltegravir serum pharmacokinetics in steady state, when co-administered with calcium carbonate formulated as antacid.

Start Date09 Dec 2020

Sponsor / Collaborator

Ottawa Hospital Research Institute

100 Clinical Results associated with Raltegravir Potassium

100 Translational Medicine associated with Raltegravir Potassium

100 Patents (Medical) associated with Raltegravir Potassium

2,829

Literatures (Medical) associated with Raltegravir Potassium

01 Nov 2026·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Outcomes for persons with triple-class resistant HIV and a history of virologic failure

Article

Author: Trickey, Adam ; Garcia, Federico ; van der Valk, Marc ; Touloumi, Giota ; Gill, M John ; Teira, Ramon ; Hessamfar, Mojgan ; Rebeiro, Peter F ; Burkholder, Greer ; Grabmeier-Pfistershammer, Katharina ; Calmy, Alexandra ; Boesecke, Christoph ; Crane, Heidi M ; Ingle, Suzanne M ; Ceccherini-Silberstein, Francesca ; Sterne, Jonathan A C ; Wittkop, Linda ; Stephan, Christoph ; Bonnet, Fabrice

OBJECTIVE:

To assess outcomes of heavily treatment experienced people with HIV (PWH) who received the antiretroviral therapy salvage regimen containing raltegravir, etravirine, and darunavir/ritonavir (known as TRIO).

METHODS:

Data were from the ART Cohort Collaboration, which is a collaboration of European and North American HIV cohort studies. Adult PWH were eligible if they had a history of virologic failure while receiving nonnucleoside reverse-transcriptase inhibitors; three or more primary protease inhibitor and nucleoside reverse transcriptase inhibitor mutations; three or fewer darunavir and nonnucleoside reverse-transcriptase inhibitor mutations; received TRIO between 2007 and 2018; virologic failure at TRIO start; and did not receive any TRIO drugs previously. Follow-up began at TRIO start. We examined rates of virologic suppression on TRIO, AIDS/death, receipt of drug-reducing regimens post-TRIO in those virologically suppressed, and subsequent virologic response. We used a competing risks framework to estimate 5-y cumulative incidence of outcomes.

RESULTS:

Among 126 eligible PWH, 24% were female, and median age was 46 y (IQR: 41-50). Median follow-up was 7.9 y (IQR: 5.1-9.3). A total of 94 (74.6%) were virologically suppressed on TRIO. Of these, 26 (28%) subsequently switched to a drug-reducing regimen, of whom 19 of 26 (73.1%) were virologically suppressed at their next viral load measure. The 5-y cumulative incidence of outcomes was stop TRIO and start another three or more drug regimen (39.1%); simplify (16.0%); stop TRIO without switching (8.8%); and death on TRIO (7.2%).

CONCLUSIONS:

Although the most common outcome after TRIO was switch to another three or more drug regimen, almost one third of virologically suppressed PWH under TRIO (with a history of multidrug resistance) switched to a drug-reducing regimen, the majority of whom maintained suppression.

06 Oct 2026·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)

Article

Author: Boumghar, Nassima ; Canetti, Diana ; Gagliardini, Roberta ; Soria, Albane ; Tiraboschi, Juan Manuel ; Gomes Pires, Elisabete ; Tiraboschi, Juan ; Averlant, Clara ; Stahlberger, Thomas ; Palich, Romain ; Domingo, Pere ; Béniguel, Lydie ; Martínez, Esteban ; Aliverti, Sylvia ; Peytavin, Gilles ; Duvivier, Claudine ; Beniguel, Lydie ; Plazzi, Maria Maddalena ; Soulié, Cathia ; Raffi, François ; Cavallec, Morane ; Tubiana, Roland ; Marcelin, Anne-Geneviève ; Hamani, Naïma ; Chivite, Ivan ; Dudoit, Yasmine ; Lê, Minh P ; Paredes Manyari, Ernesto ; Vilmin, Mélanie ; Allavena, Clotilde ; Schneider, Luminata ; Annicchiarico, Tania ; Chermak, Aziza ; Boulegroune, Abir ; Castagna, Antonella ; Ktorza, Nadine ; Assoumou, Lambert ; Antinori, Andrea ; Parisi, Maria Rita ; Louisin, Carole ; Barkat, Salima ; Qatib, Naoual ; Valantin, Marc-Antoine ; Martinez, Esteban ; Tobbal, Yasmine ; Katlama, Christine

Abstract:

Background:

We evaluated the efficacy and safety of a once-daily oral two-drug regimen (2DR) combining doravirine and raltegravir in virologically suppressed people with HIV (PWH).

Methods:

DORAL is a multicentre, open-label, randomized phase II trial conducted in France, Italy, and Spain. Virologically suppressed adults receiving stable antiretroviral therapy (ART), naïve to doravirine and without raltegravir resistance, were randomized (2:1) either to switch immediately to doravirine (100 mg) plus raltegravir (1200 mg) or to continue baseline ART until week 48 before switching to doravirine plus raltegravir. The primary endpoint was virological failure (VF; confirmed plasma HIV-1-RNA ≥50 copies/mL) at week 48. Secondary endpoints included maintenance of virological suppression through W96, immunological outcomes, safety, and pharmacokinetics in a genital sub-study.

Results:

Among 114 participants (median age, 57 years; median CD4 count, 700 cells/mm3; median duration of virological suppression, 10 years), one VF occurred by week 48 in the immediate-switch group (1.3%; 95% CI, 0.0–6.9); none occurred in the delayed-switch group. No additional VF was observed through week 96. Immunological parameters remained stable during follow-up. Three adverse events considered related to doravirine and raltegravir led to treatment discontinuation. One grade 3 adverse event (anxiety), considered related to study treatment, was reported. In the genital sub-study, drug concentrations exceeded inhibitory thresholds in most samples, with infrequent detection of low-level seminal HIV-1-RNA.

Conclusions:

This proof-of-concept phase II switch trial supports the feasibility of a once-daily doravirine plus raltegravir 2DR in selected PWH, particularly when minimizing drug-drug interactions or avoiding NRTI exposure is a priority.

01 Oct 2026·VIROLOGY

Generation and evaluation of an EcoHIV mouse model to study HIV-1 integration and expression

Article

Author: Ren, Siyao ; Liu, Jiarui ; Yang, Zihao ; Ma, Yige ; Wei, Wanrong ; Ma, Yan ; Liu, Yue ; Zhou, Ying ; Gu, Chaojiang ; Xia, Xuejiao ; Wang, Changjun ; Gao, Yang ; Li, Jiezhen ; Yu, Lei

Antiretroviral therapy suppresses HIV replication but does not purge the latent reservoirs, which remains a major barrier to cure. There is an urgent need to establish a reservoir in a mouse model for investigation of viral replication and clearance. We established an EcoHIV infection model in conventional mice by replacing HIV-1 gp120 protein with an ecotropic murine leukemia virus envelope to enable entry via the murine mCAT-1 receptor. EcoHIV can infect immunocompetent mice and multiple mutant mouse strains and replicate in CD4⁺ T cells, macrophages, and immune cells in the brain. We created and systematically validated a nested qPCR for quantitation of HIV-1/EcoHIV integration events, and we found that viral genomic integration was significantly suppressed by HIV-1 integrase inhibitors such as Raltegravir. The immunofluorescence staining indicated EcoHIV can be efficiently transmitted from infected CD4 + T cells to macrophages in vitro and EcoHIV expression was effectively inhibited by Abacavir and Raltegravir. Importantly, BLI data demonstrate that EcoHIV establishes latent reservoirs -like state in mice which can be reactivated by LRA treatment. Altogether, our model provides a valuable platform for the controlled study of HIV entry, integration, transmission, latency within tissue-resident compartments under ART and for the preclinical evaluation of latency-reversing and curative strategies.

News (Medical) associated with Raltegravir Potassium

06 Oct 2026

·www.biospace.com

Matricelf to Meet Investment Banks at NIBA’s 153rd Investment Conference Ahead of Planned Nasdaq Dual Listing and First in Human Studies

Management seeks an investment banking partner for a potential follow on offering after its planned Nasdaq dual listing to support the Company's transition into first in human studies. NESS ZIONA, ISRAEL / ACCESS Newswire / October 6, 2026 / Matricelf Ltd. (TASE:MTLF), a regenerative medicine company developing personalized, autologous engineered neural tissue for spinal cord injury, today announced that it will present at the National Investment Banking Association's 153rd Investment Conference, taking place October 6 and 7, 2026, in Fort Lauderdale, Florida. Gil Hakim, CEO, and Sigal Russo, CFO will attend the conference and meet with investors and investment banking professionals. Management will present the Company's technology, development strategy and progress toward its planned first in human clinical program. Matricelf's lead program, NewRal, combines cells derived from the patient with an extracellular matrix scaffold derived from the patient's own tissue to create a personalized neural tissue transplant. The investigational treatment is intended to replace damaged neural tissue following traumatic spinal cord injury. The Company has reported completion of its GLP safety study, initiation of GMP manufacturing activities and continued advancement of preclinical efficacy studies. In September 2026, Matricelf announced receipt of written FDA feedback supporting several key elements of its proposed first in human trial design. This feedback does not constitute authorization to initiate a clinical trial. "Matricelf is advancing toward an important transition from preclinical development to clinical evaluation," said Gil Hakim, CEO of Matricelf. "NIBA provides an opportunity to introduce our personalized approach to spinal cord repair and discuss our progress and upcoming development priorities with the investment community." Conference participants interested in meeting with management may request a meeting through the conference platform or contact Gil Hakim at Gil@matricelf.com . About Matricelf Matricelf Ltd. is a regenerative medicine company developing personalized engineered tissue therapies based on a patient's own cells and extracellular matrix. Its lead program, NewRal, targets traumatic spinal cord injury. The Company's technology originates from research at Tel Aviv University. Matricelf is publicly traded on the Tel Aviv Stock Exchange under the symbol MTLF. NewRal remains investigational, has not been approved by any regulatory authority and has not yet been evaluated in humans. For more information, visit . Forward Looking Statements This release contains forward looking statements regarding Matricelf's development strategy, manufacturing activities, planned clinical program and the potential therapeutic applications of its technology. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including research results, manufacturing challenges, regulatory requirements and financing needs. Initiation of clinical studies remains subject to applicable regulatory and ethics approvals. Matricelf undertakes no obligation to update these statements except as required by law. Investor and Media Contact Gil Hakim Chief Executive Officer Matricelf Ltd. Email: Gil@matricelf.com SOURCE: Matricelf View the original press release on ACCESS Newswire

03 Sep 2026

·www.prnewswire.com

Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program

FDA feedback supports the proposed patient population, single arm open label trial design, primary safety assessments and exploratory efficacy measures Written regulatory feedback provides guidance as Matricelf advances preparations toward a future IND submission for NewRal NESS ZIONA, Israel, Sept. 3, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing a personalized, autologous neural tissue transplant for the treatment of spinal cord injury, today announced that it has received written feedback from the U.S. Food and Drug Administration, FDA, Center for Biologics Evaluation and Research, CBER, regarding the proposed design of the Company's first in human clinical trial of NewRal. NewRal is Matricelf's investigational personalized neural tissue transplant being developed for patients with traumatic spinal cord injury. The FDA feedback was provided through a Written Response Only, WRO, interaction and was based on a limited clinical trial synopsis submitted by the Company. Based on the information provided, the FDA expressed agreement with several key components of Matricelf's proposed first in human clinical trial design, including: Proposed patient population: Adult patients with chronic, complete traumatic thoracic spinal cord injury classified as AIS A. Clinical trial design: An open label, single arm trial with an initial 12 month follow up period as a reasonable design for the initial evaluation of safety and tolerability in humans. Clinical assessments: The proposed primary safety assessments, as well as exploratory efficacy measures including ISNCSCI, MAS and SCIM III. These exploratory measures are designed to evaluate, among other parameters, neurological changes, spasticity and patients' level of functional independence. The FDA noted that these measures relate to efficacy evaluation, while the proposed early-stage clinical trial is primarily focused on safety and tolerability. The FDA also requested that Matricelf address several additional matters as part of a future Investigational New Drug, IND, submission, including trial stopping rules, objective patient discharge criteria, additional details regarding the surgical procedure and imaging criteria for patient selection. Matricelf believes the written feedback provides important regulatory guidance as the Company continues preparing its planned IND package and advances NewRal toward clinical development. Gil Hakim, Chief Executive Officer of Matricelf, commented: "The FDA's feedback represents another important step in Matricelf's transition toward clinical development. The FDA's agreement with key elements of our proposed first in human trial, including the patient population, trial structure, safety assessments and the use of exploratory efficacy measures, gives us valuable regulatory guidance as we prepare for a future IND submission. We will now incorporate the FDA's comments and continue advancing NewRal toward the clinic." About NewRal NewRal is Matricelf's investigational personalized neural tissue transplant designed to repair damaged neural tissue following spinal cord injury. The Company's platform combines patient derived cellular components, including induced pluripotent stem cells, with a biomaterial scaffold derived from the patient's own tissue to create an autologous engineered neural tissue transplant. NewRal remains investigational, has not been approved by the FDA or any other regulatory authority, and has not yet been evaluated in humans. About Matricelf Matricelf Ltd. is a regenerative medicine company developing personalized, engineered tissue therapies intended to restore function following severe tissue injury. The Company's lead program, NewRal, is being developed as an autologous engineered neural tissue transplant for traumatic spinal cord injury. Matricelf's technology is based on research originating from Tel Aviv University and combines patient derived cells with an extracellular matrix scaffold derived from the patient's own tissue. Matricelf is publicly traded on the Tel Aviv Stock Exchange under the symbol MTLF. Forward Looking Statements This press release contains forward looking statements, including statements regarding the significance of the FDA feedback, completion of requested modifications and additional information, preparation and potential submission of an IND, regulatory review of any future IND, commencement and timing of clinical trials, clinical development of NewRal and the potential safety or efficacy of the Company's technology. Forward looking statements are based on current expectations and information available to Matricelf as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, the possibility that the FDA may request additional or different information following review of a complete IND submission, delays or difficulties in product development or clinical manufacturing, results of additional studies and testing, regulatory requirements and the Company's need for additional financing. The FDA feedback described in this release was based on a limited clinical trial synopsis and does not constitute review or clearance of a complete IND application or authorization to initiate a clinical trial. There can be no assurance that an IND will be submitted, that the FDA will permit the proposed clinical trial to proceed, or that any clinical trial will begin according to the Company's anticipated timeline, if at all. CONTACT INFO: Gil Hakim CEO Matricelf Tel: +972-52-5263351 [email protected] SOURCE Matricelf Ltd. 21% more press release views with Request a Demo

Clinical Study

22 Apr 2026

·www.biospace.com

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”),” today announced the completion of enrollment in its Phase 2 clinical study (ClinicalTrials.gov Identifier: NCT06699836 ) evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC), also known as CLOVER – C CR5-targeting L eronlimab With O ral Chemotherapy and V EGF-inhibitor E nriched R egimen. The open-label, randomized, two-arm, multi-center study is evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients who have progressed following prior standard therapies. With enrollment now complete, CytoDyn will advance the study through treatment and follow-up, with resulting data expected to inform the program’s development strategy and potential next steps. “Completing enrollment in this Phase 2 study marks an important milestone for CytoDyn and for the continued development of leronlimab in oncology,” said Dr. Jacob Lalezari, Chief Executive Officer of CytoDyn. “We are grateful to the patients, investigators, and clinical sites whose commitment made completion of enrollment possible and look forward to evaluating the study results.” “CLOVER is designed to prospectively assess the activity of leronlimab in combination with an established regimen in a difficult to treat and highly refractory patient population with microsatellite stable (MSS) metastatic colorectal cancer, ” said Pashtoon M. Kasi, M.D., M.S., Principal Investigator of the study and Medical Director of GI Oncology, City of Hope Orange County, Irvine, California. “With enrollment now complete, the study is well positioned to generate meaningful insights in this patient population with a high unmet need.” The CLOVER study builds on emerging clinical and translational findings from CytoDyn’s ongoing Phase 2 mCRC program, including data being presented at the AACR Annual Meeting 2026. Preliminary results demonstrated early signals of clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, including rapid reductions in circulating tumor DNA and modulation of immune-related markers. These findings support further evaluation of CCR5 inhibition as a strategy to enhance anti-tumor activity in metastatic colorectal cancer. Leronlimab is a monoclonal antibody targeting CCR5, a receptor involved in immune cell trafficking and tumor biology. By blocking CCR5, leronlimab may help modulate the tumor microenvironment and enhance the activity of existing therapies in difficult-to-treat cancers. CytoDyn plans to share topline data from the study as they become available. About the Phase 2 mCRC Study (NCT06699836) This Phase 2 clinical study is an open-label, randomized, two-arm, multi-center study evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC), also known as CLOVER – C CR5-targeting L eronlimab With O ral Chemotherapy and V EGF-inhibitor E nriched R egimen. Approximately 60 patients were enrolled and randomized 1:1 to receive either 350 mg or 700 mg of leronlimab in combination with standard-of-care therapy. Eligible participants are adults with histologically confirmed mCRC who have progressed following prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, where appropriate, anti-EGFR therapy. The primary endpoint of the study is objective response rate (ORR), as defined by RECIST v1.1 criteria. Secondary endpoints include safety and tolerability, duration of response, and overall survival. Patients will be followed for up to 12 months. About CytoDyn CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide. For more information, please visit and follow us on LinkedIn . Note Regarding Forward-Looking Statements This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law. Corporate Contact CytoDyn Inc. ir@cytodyn.com Media Contacts David Schull or Ignacio Guerrero-Ros, Ph.D. Russo Partners, LLC CytoDyn@russopartnersllc.com

Phase 2Clinical ResultAACR

100 Deals associated with Raltegravir Potassium

External Link

KEGG	Wiki	ATC	Drug Bank
D07133	Raltegravir Potassium	J05AJ01	DB06817

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Merck Sharp & Dohme Corp.	12 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	NDA/BLA	European Union	Viatris Ltd. (New Zealand)	-
Kidney Failure, Chronic	Phase 3	France	Merck Sharp & Dohme Corp.	01 Dec 2011
Hypertriglyceridemia	Phase 3	United States	Merck Sharp & Dohme Corp.	01 May 2009
AIDS-Related Opportunistic Infections	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Canada	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	France	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Italy	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Poland	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Spain	Merck Sharp & Dohme Corp.	01 Jul 2008
HIV Seropositivity	Phase 3	-	Merck Sharp & Dohme Corp.	01 May 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IAS2026	Phase 4	HIV Infections	60	BIC/FTC/TAF plus DRV/cob	rhkcfjjswk(kjuycjljlx) = vcsjadzdgj arwhjzfaxr (raswqitzwk ) View more	Non-inferior	26 Jul 2026
				DRV/r, RAL, TDF	rhkcfjjswk(kjuycjljlx) = tmnozmhmsx arwhjzfaxr (raswqitzwk ) View more
NCT03311945 (CTgov)	Phase 3	HIV Seropositivity	33	Lamivudine+raltegravir	wwjdoqjczl = jlgulrqath ilifndhlkc (nbwswfglgn, mtraucrffj - vnrfsmzmvh) View more	-	18 Jul 2025
NCT03029689 (RAGTIME, CTgov)	Phase 3	HIV Infections	61	Current ART+raltegravir (Current ART + Raltegravir)	fmumohvogc(odrqehzlyk) = iowrttudef hfhrmujyro (qtpmizxfcn, xepuazlsqj - tthxpfsjtb) View more	-	13 Apr 2025
				Current ART (Current ART + Placebo)	fmumohvogc(odrqehzlyk) = xqojhsbqxa hfhrmujyro (qtpmizxfcn, lntkahpcpj - jmpqxbudtg) View more
NCT01854762 (PregnantHIV, CTgov)	Phase 2/3	Pregnancy \| HIV Infections	33	Raltegravir (Raltegravir)	wmkiitqymx = jgcubbierd xoqdjlylrx (aszeqxswti, wvzfupiedn - gcknvnahks) View more	-	15 Oct 2024
				Lopinavir/Ritonavir (Lopinavir/Ritonavir)	wmkiitqymx = mybrlogjkm xoqdjlylrx (aszeqxswti, kdriettwxt - rgyqtozwtf) View more
IAS2024	Not Applicable	-	13,997	2NRTI+dolutegravir	jrhmevllcm(effsqwlvly) = fcetvnlwit uxnxuchknz (hmrostcuxu )	Negative	22 Jul 2024
				2NRTI+raltegravir	jrhmevllcm(effsqwlvly) = ewnwippjmi uxnxuchknz (hmrostcuxu )
ANRS 12300 Reflate TB 2 (IAS2023)	Phase 3	HIV Infections	453	Raltegravir-based ART	dmumwbzwsy(mnnwpwninr) = iuxvgjyaml zewxrvyixj (dzhszptfck )	Positive	23 Jul 2023
				Efavirenz-based ART	dmumwbzwsy(mnnwpwninr) = thijmmjydn zewxrvyixj (dzhszptfck )
NCT01641367 (ACTG A5288, Pubmed)	Phase 4	Third line	257	RAL	zofwakklqb(eczvasjtjg) = mhszarknre qhoevludip (gxejjoaztg ) View more	-	01 Jun 2022
				DRV/r	ffgmqwworl(pximnsyodz) = zwfeoqpplk adazaonksw (zninobirnb )
NCT03374358 (Pubmed \| AIDS Patient Care STDS)	Phase 4	-	43	Switch to Raltegravir	sasishvswb(zvrpxiqiir) = gmtjhtiyrv lqxdmoybwt (efvibhkfqz ) View more	-	01 Sep 2021
				Continue unchanged antiretroviral therapy	lrhewmdgat(vuwdjzfuzu) = dmhfhipcec kyakifcaml (rohageiqoz )
NCT01147107 (CTgov)	Phase 4	HIV Infections \| Hepatitis C, Chronic	80	raltegravir (Raltegravir Based Therapy)	feiigcqhdd = nykmkpxbef nhujpprfiu (xrxguquenu, jdsuwvktjd - osbhpohncj) View more	-	13 Aug 2021
				Efavirenz (Efavirenz Based Therapy)	feiigcqhdd = izgwxhiecp nhujpprfiu (xrxguquenu, azdpyakfyg - zxuhyiswun) View more
NCT03374358 (OBERAL, CTgov)	Phase 4	Metabolic Syndrome \| Fatty Liver \| HIV Seropositivity	45	raltegravir	djtscolnhg(rsiagsjvax) = osxntinixb gqzhibtwyb (wltxriaryv, nworcrgasy - rfllmmwatm) View more	-	07 Jul 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis